Metformin suppresses interleukin‐22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway

Abstract

Collectively, our findings illuminate a new regulatory mechanism, metformin activates Hippo signaling pathway to regulate IL-22 mediated HCC progression and provide new insights into its tumor-suppressive roles.